364 related articles for article (PubMed ID: 11650075)
21. Researchers must inform subjects about financial incentives for study.
Maloney DM
Hum Res Rep; 1999 Aug; 14(8):6. PubMed ID: 11657806
[No Abstract] [Full Text] [Related]
22. Ethics review in Canada: highlights from a national workshop, part 2.
Miller JN
Ann R Coll Physicians Surg Can; 1990 Jan; 23(1):29-33. PubMed ID: 11650304
[No Abstract] [Full Text] [Related]
23. Conflicts of interest: research and clinical care.
Morris JC
Alzheimer Dis Assoc Disord; 1994; 8(Suppl. 4):49-57. PubMed ID: 11657673
[TBL] [Abstract][Full Text] [Related]
24. Patient-funded research: paying the piper or protecting the patient?
Morreim EH
IRB; 1991; 13(3):1-6. PubMed ID: 11651046
[No Abstract] [Full Text] [Related]
25. Conflict of interest in clinical research: direct payment to the investigators for finding human subjects and health information.
Puttagunta PS; Caulfield TA; Griener G
Health Law Rev; 2002; 10(2):30-2. PubMed ID: 15739309
[TBL] [Abstract][Full Text] [Related]
26. Promotion of ethics in gastroenterology: joint meeting of the members of JSGE and OMGE.
International Workshop on Promotion of Ethics in Gastroenterology, Tokyo, Japan, 8-10 Apr 1992
Gastroenterol Jpn; 1993 Jul; 28(Suppl. 6):45-54. PubMed ID: 11654959
[No Abstract] [Full Text] [Related]
27. The changing clinical trials scene: the role of the IRB.
Mitchell SC; Steingrub J
IRB; 1988; 10(4):1-5. PubMed ID: 11650078
[No Abstract] [Full Text] [Related]
28. Data monitoring committees: the moral case for maximum feasible independence.
Walters L
Stat Med; 1993 Mar; 12(5-6):575-80. PubMed ID: 11659537
[No Abstract] [Full Text] [Related]
29. Calls for strengthened drug-trial guidelines in Japan.
Netley G
Lancet; 1997 Feb; 349(9051):552. PubMed ID: 11654595
[No Abstract] [Full Text] [Related]
30. Ethics of drug experimentation.
Sgreccia E
Dolentium Hominum; 1987; 4(2nd Yr. 1):60-75. PubMed ID: 11653200
[No Abstract] [Full Text] [Related]
31. Against special protections for medical students.
Angoff NR
IRB; 1985; 7(5):9-10. PubMed ID: 11649754
[No Abstract] [Full Text] [Related]
32. Protocol review within the context of a research program.
Miller FG; Rosenstein DL
IRB; 1998; 20(4):7-10. PubMed ID: 11657088
[No Abstract] [Full Text] [Related]
33. Medical science, the clinical trial and society.
Marston RQ
Hastings Cent Rep; 1973 Apr; 3(2):1-4. PubMed ID: 11660997
[No Abstract] [Full Text] [Related]
34. Should informed consent include information on how research is funded?
Finkel MJ
IRB; 1991; 13(5):1-3. PubMed ID: 11651248
[No Abstract] [Full Text] [Related]
35. In business to treat cancer.
Henig RM
N Y Times Mag; 1986 Nov; ():68, 70, 78, 80+. PubMed ID: 11647805
[No Abstract] [Full Text] [Related]
36. Disclosure of the hidden injury.
Angoff NR
IRB; 1982 Nov; 4(9):6-7. PubMed ID: 11649502
[No Abstract] [Full Text] [Related]
37. Conflict + interest: financial incentives and informed consent in human subject research.
Benbow S
Notre Dame J Law Ethics Public Policy; 2003; 17(1):181-215. PubMed ID: 14986653
[No Abstract] [Full Text] [Related]
38. A new problem for IRBs: screening for HIV antibodies.
Meyers K
IRB; 1989; 11(6):10-1. PubMed ID: 11650285
[No Abstract] [Full Text] [Related]
39. Physicians and the pharmaceutical industry.
Canadian Medical Association
CMAJ; 1992 Feb; 146(3):388A-C. PubMed ID: 11654903
[No Abstract] [Full Text] [Related]
40. Informed consent is binding contract: Dahl v. HEM Pharmaceuticals.
Maloney DM
Hum Res Rep; 1995 Dec; 10(12):4-5. PubMed ID: 11653220
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
